Compugen Ltd. Stock

$1.41

0.00% yesterday

Nasdaq, Nov 25, 10:00 pm CET

ISIN

IL0010852080

Symbol

CGEN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Compugen Ltd. Stock price

$1.41

-4.26 75.13% 5Y

Nasdaq, Closing price Mon, Nov 25 2024

+0.00 0.00%

ISIN

IL0010852080

Symbol

CGEN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$126.25m
Enterprise Value	$16.49m
P/E (TTM) P/E ratio	73.44
EV/Sales (TTM) EV/Sales	0.28
P/S ratio (TTM) P/S ratio	2.11
P/B ratio (TTM) P/B ratio	2.09
Revenue growth (TTM) Revenue growth	698.03%
Revenue (TTM) Revenue	$59.85m
EBIT (operating result TTM) EBIT	$10.58m
Cash position	$112.71m
EPS (TTM) EPS	$0.02
P/E forward	40.29
P/S forward	3.12
EV/Sales forward	0.41
Short interest	1.47%

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Get Started for Free Today

Compugen Ltd. Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Compugen Ltd. forecast:

3x Buy

100%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Compugen Ltd. forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Compugen Ltd.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	60 60	698% 698% 100%
- Direct Costs	9.26 9.26	845% 845% 15%
Gross Profit	51 51	675% 675% 85%
- Selling and Administrative Expenses	10 10	0% 0% 17%
- Research and Development Expense	30 30	3% 3% 50%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	11 11	131% 131% 18%
Net Profit	1.60 1.60	105% 105% 3%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Compugen Ltd. Stock News

Neutral

Seeking Alpha

●

14 days ago

Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript

Start Time: 08:30 January 1, 0000 9:30 AM ET Compugen Ltd. (NASDAQ:CGEN ) Q3 2024 Earnings Call November 12, 2024, 08:30 AM ET Company Participants Anat Cohen-Dayag - President and CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Oladapo Yeku - Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, ...

Neutral

PRNewsWire

●

14 days ago

Compugen Reports Third Quarter 2024 Results

Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in tumors typically not responding to immunotherapy, aligned with previous data presented by the Company Plans to initiate, in Q2 2025, an adaptive platform trial in patients with relapsed platinum sensitive ovarian cancer in the maintenance set...

Neutral

PRNewsWire

●

15 days ago

Compugen to Participate in Stifel 2024 Healthcare Conference

HOLON, Israel , Nov. 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen management will participate in a fireside chat at the upcoming Stifel 2024 Healthcare Conference in New York City.

More Compugen Ltd. News

Company Profile

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Head office	Israel
CEO	Anat Cohen-Dayag
Employees	68
Founded	1993
Website	www.cgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now